SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells

Research output: Contribution to journalArticle

Abstract

In living cells, the N-terminal tails of core histones, the proteinaceous component of nucleosomes, are subjected to a range of covalent post-translational modifications (PTMs), which have specific roles in modulating chromatin structure and function. A growing body of evidence suggests that deregulation of histone modification patterns, upstream or downstream of DNA methylation, is a critical event in cancer initiation and progression. However, a comprehensive description of how histone modifications, singly or in combination, is disrupted in transformed cells is missing; consequently the issue whether and how specific changes in histone PTMs patterns correlate to particular tumor features is still elusive. In the present study, we focused on human breast cancer and comprehensively analyzed PTMs on histone H3 and H4 from four cancer cell lines (MCF7, MDA-MB231, MDA-MB453 and T-47D), in comparison with normal epithelial breast cells. We performed high-resolution mass spectrometry analysis of histones, in combination with stable isotope labeling with amino acids in cell culture (SILAC), to quantitatively track the modification changes in cancer cells, as compared to their normal counterpart. Our investigation focuses on lysine acetylation and methylation on fourteen distinct sites in H3 and H4. We observed significant changes for several modifications in cancer cells: while in a few cases those modifications had been previously described as a hallmark of human tumors, we could identify novel modifications, whose abundance is significantly altered in breast cancer cells. Overall, these modifications may represent part of a "breast cancer-specific epigenetic signature", with implications in the characterization of histone-related biomarkers. This work demonstrates that SILAC-based proteomics is a powerful tool to study qualitatively and quantitatively histone PTMs patterns, contributing significantly to the comprehension of epigenetic phenomena in cancer biology.

Original languageEnglish
Pages (from-to)387-399
Number of pages13
JournalAmino Acids
Volume41
Issue number2
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Histone Code
Proteomics
Histones
Cells
Breast Neoplasms
Post Translational Protein Processing
Neoplasms
Epigenomics
Isotope Labeling
Tumors
Nucleosomes
DNA Methylation
Acetylation
Methylation
Deregulation
Lysine
Chromatin
Tail
Mass Spectrometry
Biomarkers

Keywords

  • Breast cancer
  • Epigenetic mark
  • Histones
  • Mass spectrometry
  • Quantitative proteomics

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells. / Cuomo, Alessandro; Moretti, Simona; Minucci, Saverio; Bonaldi, Tiziana.

In: Amino Acids, Vol. 41, No. 2, 07.2011, p. 387-399.

Research output: Contribution to journalArticle

@article{8c52d0e62cf24cab89537f5169a7ead9,
title = "SILAC-based proteomic analysis to dissect the {"}histone modification signature{"} of human breast cancer cells",
abstract = "In living cells, the N-terminal tails of core histones, the proteinaceous component of nucleosomes, are subjected to a range of covalent post-translational modifications (PTMs), which have specific roles in modulating chromatin structure and function. A growing body of evidence suggests that deregulation of histone modification patterns, upstream or downstream of DNA methylation, is a critical event in cancer initiation and progression. However, a comprehensive description of how histone modifications, singly or in combination, is disrupted in transformed cells is missing; consequently the issue whether and how specific changes in histone PTMs patterns correlate to particular tumor features is still elusive. In the present study, we focused on human breast cancer and comprehensively analyzed PTMs on histone H3 and H4 from four cancer cell lines (MCF7, MDA-MB231, MDA-MB453 and T-47D), in comparison with normal epithelial breast cells. We performed high-resolution mass spectrometry analysis of histones, in combination with stable isotope labeling with amino acids in cell culture (SILAC), to quantitatively track the modification changes in cancer cells, as compared to their normal counterpart. Our investigation focuses on lysine acetylation and methylation on fourteen distinct sites in H3 and H4. We observed significant changes for several modifications in cancer cells: while in a few cases those modifications had been previously described as a hallmark of human tumors, we could identify novel modifications, whose abundance is significantly altered in breast cancer cells. Overall, these modifications may represent part of a {"}breast cancer-specific epigenetic signature{"}, with implications in the characterization of histone-related biomarkers. This work demonstrates that SILAC-based proteomics is a powerful tool to study qualitatively and quantitatively histone PTMs patterns, contributing significantly to the comprehension of epigenetic phenomena in cancer biology.",
keywords = "Breast cancer, Epigenetic mark, Histones, Mass spectrometry, Quantitative proteomics",
author = "Alessandro Cuomo and Simona Moretti and Saverio Minucci and Tiziana Bonaldi",
year = "2011",
month = "7",
doi = "10.1007/s00726-010-0668-2",
language = "English",
volume = "41",
pages = "387--399",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "Springer Wien",
number = "2",

}

TY - JOUR

T1 - SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells

AU - Cuomo, Alessandro

AU - Moretti, Simona

AU - Minucci, Saverio

AU - Bonaldi, Tiziana

PY - 2011/7

Y1 - 2011/7

N2 - In living cells, the N-terminal tails of core histones, the proteinaceous component of nucleosomes, are subjected to a range of covalent post-translational modifications (PTMs), which have specific roles in modulating chromatin structure and function. A growing body of evidence suggests that deregulation of histone modification patterns, upstream or downstream of DNA methylation, is a critical event in cancer initiation and progression. However, a comprehensive description of how histone modifications, singly or in combination, is disrupted in transformed cells is missing; consequently the issue whether and how specific changes in histone PTMs patterns correlate to particular tumor features is still elusive. In the present study, we focused on human breast cancer and comprehensively analyzed PTMs on histone H3 and H4 from four cancer cell lines (MCF7, MDA-MB231, MDA-MB453 and T-47D), in comparison with normal epithelial breast cells. We performed high-resolution mass spectrometry analysis of histones, in combination with stable isotope labeling with amino acids in cell culture (SILAC), to quantitatively track the modification changes in cancer cells, as compared to their normal counterpart. Our investigation focuses on lysine acetylation and methylation on fourteen distinct sites in H3 and H4. We observed significant changes for several modifications in cancer cells: while in a few cases those modifications had been previously described as a hallmark of human tumors, we could identify novel modifications, whose abundance is significantly altered in breast cancer cells. Overall, these modifications may represent part of a "breast cancer-specific epigenetic signature", with implications in the characterization of histone-related biomarkers. This work demonstrates that SILAC-based proteomics is a powerful tool to study qualitatively and quantitatively histone PTMs patterns, contributing significantly to the comprehension of epigenetic phenomena in cancer biology.

AB - In living cells, the N-terminal tails of core histones, the proteinaceous component of nucleosomes, are subjected to a range of covalent post-translational modifications (PTMs), which have specific roles in modulating chromatin structure and function. A growing body of evidence suggests that deregulation of histone modification patterns, upstream or downstream of DNA methylation, is a critical event in cancer initiation and progression. However, a comprehensive description of how histone modifications, singly or in combination, is disrupted in transformed cells is missing; consequently the issue whether and how specific changes in histone PTMs patterns correlate to particular tumor features is still elusive. In the present study, we focused on human breast cancer and comprehensively analyzed PTMs on histone H3 and H4 from four cancer cell lines (MCF7, MDA-MB231, MDA-MB453 and T-47D), in comparison with normal epithelial breast cells. We performed high-resolution mass spectrometry analysis of histones, in combination with stable isotope labeling with amino acids in cell culture (SILAC), to quantitatively track the modification changes in cancer cells, as compared to their normal counterpart. Our investigation focuses on lysine acetylation and methylation on fourteen distinct sites in H3 and H4. We observed significant changes for several modifications in cancer cells: while in a few cases those modifications had been previously described as a hallmark of human tumors, we could identify novel modifications, whose abundance is significantly altered in breast cancer cells. Overall, these modifications may represent part of a "breast cancer-specific epigenetic signature", with implications in the characterization of histone-related biomarkers. This work demonstrates that SILAC-based proteomics is a powerful tool to study qualitatively and quantitatively histone PTMs patterns, contributing significantly to the comprehension of epigenetic phenomena in cancer biology.

KW - Breast cancer

KW - Epigenetic mark

KW - Histones

KW - Mass spectrometry

KW - Quantitative proteomics

UR - http://www.scopus.com/inward/record.url?scp=79960281535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960281535&partnerID=8YFLogxK

U2 - 10.1007/s00726-010-0668-2

DO - 10.1007/s00726-010-0668-2

M3 - Article

C2 - 20617350

AN - SCOPUS:79960281535

VL - 41

SP - 387

EP - 399

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

IS - 2

ER -